4.7 Article

Combined Administration of Vitamin D3 and Geniposide Is Less Effective than Single Use of Vitamin D3 or Geniposide in the Treatment of Ulcerative Colitis

Journal

FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.714065

Keywords

ulcerative colitis; vitamin D; p38 MAPK; vitamin D receptor; geniposide (GE)

Funding

  1. Natural Science Foundation of Guangdong Province China [2019A1515012082, 2019A1515110653]
  2. project of Education Department of Guangdong Province [2019KTSCX026]
  3. project of Social Science and Technology Development Project of Dongguan China [2019507101570]
  4. Project of Traditional Chinese Medicine Bureau of Guangdong Province China [20190409212302]

Ask authors/readers for more resources

The single use of geniposide and vitamin D-3 showed significant improvement in symptoms of UC, while the combination treatment had less beneficial effects on UC in mice. Geniposide could inhibit the activation of p38 MAPK and restrict the vitamin D receptor signaling stimulated by vitamin D-3.
With the increasing incidence of ulcerative colitis (UC) in China, Chinese medicinal herbs or relatively active compounds are widely applied in treating UC. These medicines may be combined with other therapeutic agents such as vitamin D-3. Nevertheless, the efficacy of these combinations for UC is unclear. Geniposide is an active component in many Chinese herbal medicines. It could ameliorate dextran sulfate sodium (DSS)-induced colitis in mice. This study was designed to determine the efficacy and mechanism of the single use and combination of geniposide and vitamin D-3 on a mouse model of acute colitis. Data showed that a single administration of geniposide (2 mg/kg) or vitamin D-3 (4 IU/day) could significantly improve the symptoms of UC and relieve colon damage. Geniposide and vitamin D could significantly decrease the levels of TNF-alpha and IL-6 in serum and colon, and increase the level of IL-10 in the colon. However, the combined treatment of geniposide (2 mg/kg) and vitamin D-3 (4 IU/day) exerted less beneficial effects on UC in mice, indicating by less improvement of UC symptoms, colon damage, and inflammatory infiltration. The combination only downregulated the level of TNF-alpha in serum and IL-6 in the colon. Our data further demonstrated that geniposide could inhibit the activation of p38 MAPK and then restrict the vitamin D receptor signaling stimulated by vitamin D-3. These results implied that the combination of geniposide and vitamin D-3 might not be an ideal combined treatment for acute colitis, and the combination of vitamin D supplementary and geniposide (or herbal medicines rich in geniposide) need more evaluation before being applied to treat UC in clinic.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available